Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Discovery
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Allosteric TYK2 inhibitor discovered by leveraging Atomwise’s proprietary AI drug discovery platform AtomNet®, into clinical trials, which is investigated for autoimmune disease.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 03, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Discovery
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Discovery Platform
Sponsor : Sanofi
Deal Size : $1,020.0 million
Deal Type : Collaboration
Details : The Atomwise approach shifts the mode of drug discovery away from serendipitous discovery and toward search based on structure, making the drug discovery process more rational, effective, and efficient.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : $20.0 million
August 17, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery Platform
Sponsor : Sanofi
Deal Size : $1,020.0 million
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : FutuRx
Deal Size : Undisclosed
Deal Type : Collaboration
Atomwise and FutuRx Launch A2i Therapeutics
Details : As part of the strategic partnership, Atomwise will work closely with the FutuRx management team, investors and incubated portfolio companies to apply its AI technology to early-stage drug discovery projects.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 18, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : FutuRx
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : Bill & Melinda Gates Foundation
Deal Size : $2.3 million
Deal Type : Funding
Atomwise Receives a $2.3M Grant to Develop New Therapies for Drug Resistant Malaria and Tuberculosis
Details : The grant funding will be used to discover novel compounds that can advance the development of novel antimalarial and anti-tuberculosis small molecule therapies in collaboration with the Gates Foundation’s global network of partners and funded investig...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 06, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : Bill & Melinda Gates Foundation
Deal Size : $2.3 million
Deal Type : Funding
LOOKING FOR A SUPPLIER?